Table 1.

Patient characteristics of the response evaluated AVETUX cohort and the central review cohort.

Baseline Characteristics
	Total AVETUX cohort	Central review cohort
Sex, n (%)
Male	26 (66.7)	22 (66.7)
Female	13 (33.2)	11 (33.2)
Age
Median years (range)	62 (29-82)	61 (29-74)
Microsattelite status, n (%)
MSI-H	2 (5)	2 (6)
MSI-L	1 (3)	1 (3)
MSS	36 (92)	30 (91)
Prior adjuvant therapy, n (%)
Oxaliplatin based	9 (23)	8 (24)
Metastatic sites, n (%)
Liver	30 (77)	26 (79)
Liver only	13 (33)	10 (30)
Lung	12 (31)	11 (33)
Lymph node	18 (46)	18 (55)
Primary site, n (%)
Right	3 (8)	2 (6)
Left	36 (92)	31 (94)
Surgery on primary tumor, n (%)	31 (79)	25 (75)
More than 1 metastatic site, n (%)	19 (49)	16 (48)